The trajectory of companies tied to the drug's legacy presents a intricate investment picture . While the initial boom generated substantial returns , generic competition have significantly diminished revenue. Investing in connected pharmaceutical companies now requires a discerning assessment of patent rights , evolving healthcare trends , and the